WO2018231176A3 - Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation - Google Patents
Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation Download PDFInfo
- Publication number
- WO2018231176A3 WO2018231176A3 PCT/TR2017/050637 TR2017050637W WO2018231176A3 WO 2018231176 A3 WO2018231176 A3 WO 2018231176A3 TR 2017050637 W TR2017050637 W TR 2017050637W WO 2018231176 A3 WO2018231176 A3 WO 2018231176A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diclofenac
- inflammation
- pain
- combinations
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A single unit pharmaceutical dosage form comprising: diclofenac or a pharmaceutically acceptable salt thereof; and an H2 receptor antagonist, preferably famotidine or a pharmaceutically acceptable salt thereof, wherein diclofenac has a Tmax of between about and 50 minutes after administering said formulation to a patient.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201991384A EA201991384A1 (en) | 2016-12-07 | 2017-12-07 | COMBINATIONS OF DICLOFENAC AND H2-RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN AND INFLAMMATION |
US16/465,862 US20190307713A1 (en) | 2016-12-07 | 2017-12-07 | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2016/18037 | 2016-12-07 | ||
TR2016/18037A TR201618037A2 (en) | 2016-12-07 | 2016-12-07 | DICLOFENAC AND H2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN AND INFLAMMATION |
TR2017/11764A TR201711764A2 (en) | 2016-12-07 | 2017-08-09 | Diclofenac and h2 receptor antagonists for treatment of pain and inflammation |
TR2017/11764 | 2017-08-09 | ||
TR2017/17134 | 2017-11-02 | ||
TR2017/17134A TR201717134A2 (en) | 2016-12-07 | 2017-11-02 | Rapid Release Oral Combinations of Diclofenac and H2 Receptor Antagonists for Rapid Treatment of Pain and Inflammation |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2018231176A2 WO2018231176A2 (en) | 2018-12-20 |
WO2018231176A3 true WO2018231176A3 (en) | 2019-02-21 |
WO2018231176A9 WO2018231176A9 (en) | 2019-04-04 |
Family
ID=64605656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/TR2017/050637 WO2018231176A2 (en) | 2016-12-07 | 2017-12-07 | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation |
Country Status (2)
Country | Link |
---|---|
TR (1) | TR201717134A2 (en) |
WO (1) | WO2018231176A2 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064815A1 (en) * | 2003-01-21 | 2004-08-05 | Smartrix Technologies Inc. | Oral dosage formulation |
WO2008004231A1 (en) * | 2006-07-07 | 2008-01-10 | Tiltan Pharma Ltd. | Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent |
WO2012144964A1 (en) * | 2011-04-18 | 2012-10-26 | Ak Kimya Ithalat-Lhracat Ve Sanayii A.S. | Thiocolchicoside, diclofenac and lansoprazole combinations |
WO2013111070A1 (en) * | 2012-01-23 | 2013-08-01 | Ranbaxy Laboratories Limited | In-situ multilayered tablet technology |
US20150290174A1 (en) * | 2014-04-11 | 2015-10-15 | Resuscitate MOE LLC | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2260837A1 (en) | 2001-06-01 | 2010-12-15 | Pozen, Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US20050163847A1 (en) | 2004-01-21 | 2005-07-28 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and an antiulcerative drug |
US20090233970A1 (en) | 2008-03-11 | 2009-09-17 | Nickell Robert P | Combined nsaid and acid blocker formulation and method |
-
2017
- 2017-11-02 TR TR2017/17134A patent/TR201717134A2/en unknown
- 2017-12-07 WO PCT/TR2017/050637 patent/WO2018231176A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004064815A1 (en) * | 2003-01-21 | 2004-08-05 | Smartrix Technologies Inc. | Oral dosage formulation |
WO2008004231A1 (en) * | 2006-07-07 | 2008-01-10 | Tiltan Pharma Ltd. | Anti-cancer therapy comprising an h2-blocker, at least one antiinflammatory agent and a cytotoxic agent |
WO2012144964A1 (en) * | 2011-04-18 | 2012-10-26 | Ak Kimya Ithalat-Lhracat Ve Sanayii A.S. | Thiocolchicoside, diclofenac and lansoprazole combinations |
WO2013111070A1 (en) * | 2012-01-23 | 2013-08-01 | Ranbaxy Laboratories Limited | In-situ multilayered tablet technology |
US20150290174A1 (en) * | 2014-04-11 | 2015-10-15 | Resuscitate MOE LLC | Pharmaceutical formulations and method of using the same for alleviating symptoms of hangover, stomach flu or migraine |
Non-Patent Citations (2)
Title |
---|
CHAPLE D R ET AL: "Development of stabilating indicating analytical method for famotidine and diclofenac potasium in combined dosage form", INDIAN DRUGS, vol. 49, no. 6, 31 May 2012 (2012-05-31), pages 40 - 42, XP009510566, ISSN: 0019-462X, Retrieved from the Internet <URL:http://www.indiandrugsonline.org/issuesarticle-details?id=MjI3> [retrieved on 20190118] * |
SURYAKUMAR J ET AL: "FAMOTIDINE AFFECTS THE PHARMACOKINETICS OF DICLOFENAC SODIUM", DRUG INVESTIGAT, ADIS INTERNATIONAL, NZ, vol. 4, no. 1, 1 January 1992 (1992-01-01), pages 66 - 68, XP008031074, ISSN: 0114-2402 * |
Also Published As
Publication number | Publication date |
---|---|
TR201717134A2 (en) | 2018-07-23 |
WO2018231176A2 (en) | 2018-12-20 |
WO2018231176A9 (en) | 2019-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200600T1 (en) | Tapentadol for preventing and treating depression and anxiety | |
WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
MX2015002378A (en) | Anxiolytic composition, formulation and method of use. | |
WO2011157416A3 (en) | Transdermal administration of memantine | |
EA201270221A1 (en) | TREATMENT OF CROWN DISEASE WITH LACQUINIMODE | |
AU2018231044A8 (en) | Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol | |
PE20150161A1 (en) | USE OF HIGH DOSE LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS | |
NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
BR112013010829B8 (en) | Intravenous pharmaceutical composition to provide relief from pain and/or inflammation | |
MX2021002321A (en) | Novel methods. | |
PH12021550047A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS | |
MX2022015629A (en) | Use of vibegron to treat overactive bladder. | |
WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
NZ726132A (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
JP2016505050A5 (en) | ||
NZ751972A (en) | Treatment of prurigo nodularis | |
WO2018231176A3 (en) | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation | |
MX2018005298A (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. | |
MX2018011293A (en) | Prolonged release pharmaceutical composition comprising cysteamine or salt thereof. | |
HRP20211661T1 (en) | Igmesine for use in the treatment of alzheimer's disease | |
WO2020013776A3 (en) | Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation | |
EA201991384A1 (en) | COMBINATIONS OF DICLOFENAC AND H2-RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN AND INFLAMMATION | |
WO2019203759A3 (en) | Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation. | |
AR104177A1 (en) | SYSTEM FOR THE ADMINISTRATION OF DRUGS IN THE LAGRIMAL GLAND | |
MX2021007324A (en) | Oral therapy using 6,8-bis-benzylthio-octanoic acid. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205N DATED 19/07/2019) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17909666 Country of ref document: EP Kind code of ref document: A2 |